AOD-9604: The Fat Loss Fragment of Growth Hormone

The Concept Behind AOD-9604

AOD-9604 represents one of the more intellectually elegant approaches in peptide research: taking a large, multifunctional hormone and isolating the specific fragment responsible for a single desired effect. Human growth hormone is a 191-amino-acid protein with diverse biological activities, including growth promotion, muscle anabolism, lipolysis (fat breakdown), and anti-lipogenesis (inhibiting new fat formation). Many of these effects, particularly the anabolic and diabetogenic ones, are mediated through IGF-1 signaling. The lipolytic activity, however, appears to operate through a distinct, IGF-1-independent pathway.

In the 1990s, researchers at Monash University in Melbourne identified that the C-terminal region of growth hormone, specifically amino acids 177-191, retained the lipolytic and anti-lipogenic properties of the full molecule without stimulating IGF-1 production or triggering the metabolic side effects associated with GH therapy. They synthesized this fragment with an additional tyrosine residue at position 177 to improve stability, creating what became known as AOD-9604.

Preclinical Evidence

The animal data for AOD-9604 was promising. Studies in obese (ob/ob) mice and Zucker fatty rats showed consistent fat mass reduction without affecting lean mass, food intake, IGF-1 levels, or blood glucose. The preclinical results were published in several papers from the Monash University group between 1998 and 2001.

The most striking aspect of the preclinical data was the selectivity. Full-length growth hormone produces lipolysis but also raises IGF-1, worsens insulin sensitivity, promotes fluid retention, and can cause joint pain and carpal tunnel syndrome. AOD-9604 appeared to deliver the fat loss without any of these baggage effects. In every animal model tested, IGF-1 levels, blood glucose, and insulin sensitivity were unaffected.

AOD-9604 retained growth hormone’s ability to burn fat and block new fat formation while stripping away the growth, anabolic, and diabetogenic properties of the full molecule.

How It Works

The lipolytic mechanism of AOD-9604 has been partially characterized but remains incompletely understood. The compound stimulates lipolysis (the breakdown of stored triglycerides into free fatty acids and glycerol) and inhibits lipogenesis (the formation of new fat from dietary carbohydrates and fats). Both actions mirror what the corresponding region of full-length GH does, but without engaging the GH receptor or stimulating IGF-1 production.

The working hypothesis is that the C-terminal fragment interacts with a receptor or binding site distinct from the classical GH receptor. Some evidence points toward the beta-3 adrenergic receptor pathway, which is known to mediate lipolysis in adipose tissue. However, the exact binding partner has not been confirmed, and the signaling cascade downstream of AOD-9604 remains an area of active investigation.

Human Clinical Trials

The clinical development of AOD-9604 was led by Metabolic Pharmaceuticals, an Australian biotech company. The compound entered human trials with strong preclinical data and a compelling mechanistic rationale. The results, however, did not match the promise.

Phase 1 trials confirmed safety and tolerability. The compound was well-tolerated at oral doses up to 54 mg/day, with no serious adverse events and no effects on IGF-1, glucose, or insulin. This validated the selectivity observed in animals.

Phase 2b trials enrolled 536 obese adults across multiple centers. Participants received oral AOD-9604 at doses of 1 mg, 5 mg, or 25 mg, or placebo, for 12 weeks. The primary endpoint was change in body weight.

Why Preclinical Results Didn’t Translate

The gap between the animal and human data for AOD-9604 is one of the more instructive examples in peptide research of the challenges in translating preclinical findings to clinical efficacy. Several factors may explain the discrepancy.

The contrast with GLP-1 agonists is instructive. Compounds like semaglutide and tirzepatide produce 15-22% weight loss not primarily through lipolysis but through centrally mediated appetite suppression. AOD-9604 does not affect appetite. This difference likely explains a significant portion of the efficacy gap.

The Australian TGA Decision

In 2007, Australia’s Therapeutic Goods Administration (TGA) granted AOD-9604 Generally Recognized As Safe (GRAS) status, classifying it as a food-grade ingredient. This decision was based on the safety data from clinical trials showing no serious adverse events, no effects on IGF-1 or glucose metabolism, and no toxicological concerns.

This regulatory status is sometimes cited as validation, but it is important to understand what it means and what it does not. GRAS classification speaks to safety, not efficacy. It means the compound does not appear to cause harm, not that it produces a specific therapeutic benefit. The TGA decision did not constitute approval of AOD-9604 as a drug for obesity or any other indication.

Comparison to Tesamorelin

For context on how GH-based fat loss strategies have fared in clinical development, tesamorelin offers an informative comparison. Tesamorelin is a GHRH analog (not a GH fragment) that stimulates endogenous GH production. It is FDA-approved for HIV-associated lipodystrophy, where it reduces visceral adipose tissue by approximately 15-18% over 26 weeks.

Tesamorelin works through a different mechanism than AOD-9604: it increases GH secretion, which then drives lipolysis systemically. The key difference is that tesamorelin does raise IGF-1, whereas AOD-9604 does not. Tesamorelin succeeded clinically in a specific population (HIV lipodystrophy) where visceral fat accumulation is a well-defined pathology, whereas AOD-9604 was tested in general obesity, a more heterogeneous condition.

AOD-9604 demonstrated an exceptional safety profile but failed to produce clinically significant fat loss in humans, illustrating the gap between preclinical promise and clinical reality in obesity pharmacology.

Current Status

AOD-9604 is not FDA-approved for any indication. Metabolic Pharmaceuticals discontinued development after the Phase 2b results. The compound has since been explored for other potential applications, including osteoarthritis (based on evidence that the GH C-terminal region promotes cartilage repair) and general wellness, but no subsequent clinical program has advanced to registration trials.

The peptide remains available as a research compound and, under the TGA classification, as a food-grade ingredient in Australia. Its safety profile is well-established. Its efficacy for fat loss in humans, based on the published clinical evidence, has not been demonstrated at a level that meets conventional regulatory standards.

For full molecular details, see our AOD-9604 research profile. For the FDA-approved GH-axis approach to fat reduction, our tesamorelin page covers the GHRH analog currently used in clinical practice.

This article is for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, or prevent any condition. Always consult with a qualified healthcare professional before making health-related decisions. Clinical trial data referenced here is sourced from peer-reviewed publications and may not reflect the most current findings.